At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RGLS Regulus Therapeutics
Not Yet Opened 11-25 16:00:00 EST
1.52
+0.05
+3.40%
盘后1.55
+0.03+1.97%
19:35 EST
High1.54
Low1.45
Vol261.97K
Open1.49
D1 Closing1.47
Amplitude6.12%
Mkt Cap99.56M
Tradable Cap73.97M
Total Shares65.50M
T/O395.51K
T/O Rate0.54%
Tradable Shares48.66M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Regulus Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1B Multiple-Ascending Dose (Mad) Clinical Trial of Rgls8429 for the Treatment of Patients With Autosomal Dominant Polycystic Kidney Disease (Adpkd)
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.